Novo Nordisk A/S has introduced a multi-month subscription program for its obesity treatment, Wegovy, aimed at enhancing affordability and treatment adherence for self-pay patients. This strategy comes as the company faces intense competition from Eli Lilly's newly approved obesity pill, Foundayo, which threatens Novo's market share. While the subscription model may help regain lost momentum and improve pricing predictability amidst challenges like generic competition and patent expirations, its success will depend on how effectively it can address the competitive landscape.
“But no people bought the pump after the $NVO news.”
“other giants like Novo Nordisk and Eli Liy in terms of like PE ratios, they trade anywhere from like two to five times higher than Fizer right now.”
“Earlier this year, Novo Nordisk pulled off the best obesity-drug launch ever with its Wegovy pill...”
“Novo Nordisk A/S, which launched an obesity pill earlier this year.”
“Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator”
“Novo Nordisk rose as much as 4% after England’s drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes.”
“Doustdar took over as CEO last year following a challenging stretch for Novo, during which it ceded market leadership to Eli Lilly and faced setbacks in clinical trials. The company is now aiming to regain momentum, including through the rollout of an oral version of Wegovy.”
“Novo is also preparing to reduce U.S. list prices significantly. Wholesale prices for Wegovy are expected to drop by about half, while Ozempic will see a reduction of roughly a third starting next year.”
“At the same time, Novo faces growing pressure from patent expirations. The key ingredient in both Ozempic and Wegovy, semaglutide, has recently lost exclusivity in several major markets, including Canada, India, Brazil and China.”
“To navigate these challenges, Novo has also pursued partnerships. In Brazil, it is working with Eurofarma to market its drugs under new brand names, while in India it has teamed up with Emcure Pharma and Abbott to expand distribution.”
“The problem facing Novo Nordisk is that its next potential winner is still quite far away; drug development takes years. That means Eli Lilly could be running circles around Novo Nordisk with orforglipron and retatrutide for the foreseeable future.”
“The fight between these two GLP-1 stocks has now entered round two. Novo Nordisk's Wegovy pill received approval in December, making it the first GLP-1 pill for weight loss. Now, Eli Lilly has punched back with Foundayo (orforglipron), its newly approved GLP-1 pill that will be available starting April 6.”
